Description
The clinical trialist identified absence of condensate biomarkers as a major barrier to therapeutic development. Without measurable endpoints, clinical trials targeting phase separation mechanisms cannot be designed or monitored effectively.
Source: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062229-3ab00c95 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062229-3ab00c95)
Evidence summary
Resolved by hypothesis h-var-e2b5a7e7db: GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance. Score: 0.964. Supporting PMIDs: 19449329, 23431156, 26282667, 40994429, 40796363.